|
Roldán V, Marín F, Díaz J, Gallego P, Jover E, Romera M, Manzano-Fernández S, Casas T, Valdés M, Vicente V, Lip GY. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost. 2012 Aug;10(8):1500-7. doi: 10.1111/j.1538-7836.2012.04812.x. PubMed PMID: 22681487.
AÑO: 2012; IF: 6.081
|
22681487
|
Pérez-Andreu V, Teruel R, Corral J, Roldán V, García-Barberá N, Salloum-Asfar S, Gómez-Lechón MJ, Bourgeois S, Deloukas P, Wadelius M, Vicente V, González-Conejero R, Martínez C. miR-133a regulates vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle. Mol Med. 2013 Jan 22;18:1466-72. doi: 10.2119/molmed.2012.00062. PubMed PMID: 23154637; PubMed Central PMCID: PMC3563709.
AÑO: 2012; IF: 4.469
|
|
Roldán V, Marín F. Oral anticoagulation in chronic kidney disease: A huge challenge. Thromb Haemost. 2012 Jul;108(1):3-5. doi: 10.1160/TH12-05-0324. Epub 2012 May 25. PubMed PMID: 22628077.
AÑO: 2012; IF: 6.094
|
|
Roldán Schilling V, Vicente García V. [Pharmacodynamic and pharmacokinetic characteristics. Mechanism of action of the new oral anticoagulants]. Med Clin (Barc). 2012 Oct;139 Suppl 2:10-2. doi: 10.1016/S0025-7753(12)70035-0. Review. Spanish. PubMed PMID: 23498066.
AÑO: 2012; IF: 1.399
|
|
Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011 Jun 21;57(25):2496-504. doi: 10.1016/j.jacc.2010.12.033. Epub 2011 Apr 14. PubMed PMID: 21497043.
AÑO: 2011; IF: 14.156
|